Table of contents

Extended reports

• UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte (1 June, 2003)

  R L Neame, A J Carr, K Muir, M Doherty
• Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? (1 June, 2003)

  A van Tubergen, L Heuft-Dorenbosch, G Schulpen, R Landewé, R Wijers, D van der Heijde, J van Engelshoven, Sj van der Linden
• Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis (1 June, 2003)

  L Padyukov, J Lampa, M Heimbürger, S Ernestam, T Cederholm, I Lundkvist, P Andersson, Y Hermansson, A Harju, L Klareskog, J Bratt
• Long term outcome of catastrophic antiphospholipid syndrome survivors (1 June, 2003)

  D Erkan, R A Asherson, G Espinosa, R Cervera, J Font, J-C Piette, M D Lockshin
• Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk (1 June, 2003)

  M Bijl, G Horst, H Bootsma, P C Limburg, C G M Kallenberg
• Value of IgA anticardiolipin and anti-β₂-glycoprotein I antibody testing in patients with pregnancy morbidity

  (1 June, 2003)

  S Carmo-Pereira, M L Bertolaccini, A Escudero-Contreras, M A Khamashta, G R V Hughes
• Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources (1 June, 2003)

  J Ruof, J L Hülsemann, T Mittendorf, S Handelmann, J M von der Schulenburg, H Zeidler, S Merkesdal
• Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia (1 June, 2003)

  S Ozgocmen, T Yoldas, A Kamanli, H Yildizhan, R Yigiter, O Ardicoglu
• Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis (1 June, 2003)

  P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D’Cruz, G R V Hughes